Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Intellia Therapeutics Inc (NASDAQ: NTLA) was $13.12 for the day, down -6.02% from the previous closing price of $13.96. In other words, the price has decreased by -$6.02 from its previous closing price. On the day, 16.62 million shares were traded. NTLA stock price reached its highest trading level at $14.0 during the session, while it also had its lowest trading level at $12.6265.
Ratios:
Our analysis of NTLA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.19 and its Current Ratio is at 5.19. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.11.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 01 ’25 when Schultes Birgit C sold 31 shares for $17.38 per share. The transaction valued at 539 led to the insider holds 105,184 shares of the business.
Dube Michael P sold 1,871 shares of NTLA for $32,518 on Oct 01 ’25. The VP, Chief Accounting Officer now owns 55,266 shares after completing the transaction at $17.38 per share. On Aug 20 ’25, another insider, CHASE WILLIAM J, who serves as the Director of the company, bought 100,000 shares for $10.03 each. As a result, the insider paid 1,003,000 and bolstered with 134,693 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NTLA now has a Market Capitalization of 1408391168 and an Enterprise Value of 1051331136. For the stock, the TTM Price-to-Sale (P/S) ratio is 26.64 while its Price-to-Book (P/B) ratio in mrq is 1.93. Its current Enterprise Value per Revenue stands at 19.89 whereas that against EBITDA is -2.095.
Stock Price History:
The Beta on a monthly basis for NTLA is 2.43, which has changed by -0.07735586 over the last 52 weeks, in comparison to a change of 0.20772064 over the same period for the S&P500. Over the past 52 weeks, NTLA has reached a high of $28.25, while it has fallen to a 52-week low of $5.90. The 50-Day Moving Average of the stock is -22.87%, while the 200-Day Moving Average is calculated to be 14.47%.
Shares Statistics:
NTLA traded an average of 6.58M shares per day over the past three months and 12091820 shares per day over the past ten days. A total of 105.33M shares are outstanding, with a floating share count of 101.56M. Insiders hold about 5.39% of the company’s shares, while institutions hold 90.21% stake in the company. Shares short for NTLA as of 1760486400 were 30904192 with a Short Ratio of 4.70, compared to 1757894400 on 34137856. Therefore, it implies a Short% of Shares Outstanding of 30904192 and a Short% of Float of 32.61.
Earnings Estimates
The market rating of Intellia Therapeutics Inc (NTLA) is currently shaped by the ongoing analysis conducted by 19.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.96, with high estimates of $0.04 and low estimates of -$1.2.
Analysts are recommending an EPS of between -$2.67 and -$4.71 for the fiscal current year, implying an average EPS of -$4.09. EPS for the following year is -$3.92, with 22.0 analysts recommending between -$2.37 and -$5.05.
Revenue Estimates
A total of 22 analysts have provided revenue estimates for NTLA’s current fiscal year. The highest revenue estimate was $210M, while the lowest revenue estimate was $30.87M, resulting in an average revenue estimate of $62.17M. In the same quarter a year ago, actual revenue was $57.88M
